Back to resultsEfficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Primary Purpose
Esophagitis, Reflux, Esophagitis, Peptic
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Dexlansoprazole MR
Dexlansoprazole MR
Lansoprazole
Sponsored by
About this trial
This is an interventional treatment trial for Esophagitis, Reflux focused on measuring Erosive Esophagitis
Eligibility Criteria
Inclusion Criteria: Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D) Exclusion Criteria: Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori. Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics Use of antacids [except for study supplied Gelusil®] Need for continuous anticoagulant therapy (blood thinners) Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter) Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition. History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer. Acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Dexlansoprazole MR 60 mg QD
Dexlansoprazole MR 90 mg QD
Lansoprazole 30 mg QD
Arm Description
Outcomes
Primary Outcome Measures
Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed.
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Secondary Outcome Measures
Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
Percentage of subjects with baseline EE grade C or D combined who have complete healing of erosive esophagitis as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analyses.
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method.
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00251693
Brief Title
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Official Title
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
December 2005 (undefined)
Primary Completion Date
January 2007 (Actual)
Study Completion Date
January 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Takeda
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
Detailed Description
This is a Phase 3, randomized, double-blind, multi-center, active-controlled, 3-arm study with an 8-week treatment period. This study will compare the efficacy of dexlansoprazole MR (60 mg QD and 90 mg QD) with that of lansoprazole (30 mg) when administered orally as a single daily dose in the morning, before breakfast. The study is designed to evaluate healing of erosive esophagitis and the effect of the therapy on relieving gastroesophageal reflux disease-related symptoms. The study consists of two periods, a screening period (maximum 21 days) and a treatment period, which will last 8 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophagitis, Reflux, Esophagitis, Peptic
Keywords
Erosive Esophagitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2038 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dexlansoprazole MR 60 mg QD
Arm Type
Experimental
Arm Title
Dexlansoprazole MR 90 mg QD
Arm Type
Experimental
Arm Title
Lansoprazole 30 mg QD
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Dexlansoprazole MR
Other Intervention Name(s)
TAK-390MR, Kapidex, Dexilant
Intervention Description
Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
Intervention Type
Drug
Intervention Name(s)
Dexlansoprazole MR
Other Intervention Name(s)
TAK-390MR, Kapidex, Dexilant
Intervention Description
Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
Intervention Type
Drug
Intervention Name(s)
Lansoprazole
Other Intervention Name(s)
Prevacid, AG-1749
Intervention Description
Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Primary Outcome Measure Information:
Title
Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
Description
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed.
Time Frame
8 Weeks
Title
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.
Description
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
Description
Percentage of subjects with baseline EE grade C or D combined who have complete healing of erosive esophagitis as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Time Frame
8 Weeks
Title
Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.
Description
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Time Frame
8 Weeks
Title
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analyses.
Description
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Time Frame
4 Weeks
Title
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method.
Description
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed.
Time Frame
4 Weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D)
Exclusion Criteria:
Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori.
Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics
Use of antacids [except for study supplied Gelusil®]
Need for continuous anticoagulant therapy (blood thinners)
Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus
History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)
Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.
History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.
Acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Takeda
Official's Role
Study Chair
Facility Information:
City
Alabaster
State/Province
Alabama
Country
United States
City
Birmingham
State/Province
Alabama
Country
United States
City
Huntsville
State/Province
Alabama
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Scottsdale
State/Province
Arizona
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Anaheim
State/Province
California
Country
United States
City
Chula Vista
State/Province
California
Country
United States
City
Fullerton
State/Province
California
Country
United States
City
Garden Grove
State/Province
California
Country
United States
City
Irvine
State/Province
California
Country
United States
City
Lancaster
State/Province
California
Country
United States
City
Long Beach
State/Province
California
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
Mission Hills
State/Province
California
Country
United States
City
Palm Springs
State/Province
California
Country
United States
City
Pasadena
State/Province
California
Country
United States
City
Redwood City
State/Province
California
Country
United States
City
San Diego
State/Province
California
Country
United States
City
San Luis Obispo
State/Province
California
Country
United States
City
Boulder
State/Province
Colorado
Country
United States
City
Colorado Springs
State/Province
Colorado
Country
United States
City
Lone Tree
State/Province
Colorado
Country
United States
City
Wheat Ridge
State/Province
Colorado
Country
United States
City
Waterbury
State/Province
Connecticut
Country
United States
City
Boynton Beach
State/Province
Florida
Country
United States
City
Jacksonsville
State/Province
Florida
Country
United States
City
Jupiter
State/Province
Florida
Country
United States
City
Kissimmee
State/Province
Florida
Country
United States
City
Lakeland
State/Province
Florida
Country
United States
City
New Port Richey
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Honolulu
State/Province
Hawaii
Country
United States
City
Arlington Heights
State/Province
Illinois
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Hines
State/Province
Illinois
Country
United States
City
Oak Park
State/Province
Illinois
Country
United States
City
Rockford
State/Province
Illinois
Country
United States
City
Clive
State/Province
Iowa
Country
United States
City
Dubuque
State/Province
Iowa
Country
United States
City
Newton
State/Province
Kansas
Country
United States
City
Shawnee Mission
State/Province
Kansas
Country
United States
City
Topeka
State/Province
Kansas
Country
United States
City
Metairie
State/Province
Louisiana
Country
United States
City
Shreveport
State/Province
Louisiana
Country
United States
City
Hollywood
State/Province
Maryland
Country
United States
City
Lutherville
State/Province
Maryland
Country
United States
City
Troy
State/Province
Michigan
Country
United States
City
Chaska
State/Province
Minnesota
Country
United States
City
Jackson
State/Province
Mississippi
Country
United States
City
Mexico
State/Province
Missouri
Country
United States
City
Saint Louis
State/Province
Missouri
Country
United States
City
Washington
State/Province
Missouri
Country
United States
City
Omaha
State/Province
Nebraska
Country
United States
City
Pahrump
State/Province
Nevada
Country
United States
City
Binghamton
State/Province
New York
Country
United States
City
Brooklyn
State/Province
New York
Country
United States
City
Great Neck
State/Province
New York
Country
United States
City
Rochester
State/Province
New York
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Elkin
State/Province
North Carolina
Country
United States
City
Greensboro
State/Province
North Carolina
Country
United States
City
Hickory
State/Province
North Carolina
Country
United States
City
Salisbury
State/Province
North Carolina
Country
United States
City
Statesville
State/Province
North Carolina
Country
United States
City
Winston-Salem
State/Province
North Carolina
Country
United States
City
Beachwood
State/Province
Ohio
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Mayfield Heights
State/Province
Ohio
Country
United States
City
Warren
State/Province
Ohio
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Portland
State/Province
Oregon
Country
United States
City
Beaver Falls
State/Province
Pennsylvania
Country
United States
City
Duncansville
State/Province
Pennsylvania
Country
United States
City
Lansdale
State/Province
Pennsylvania
Country
United States
City
Bristol
State/Province
Tennessee
Country
United States
City
Chattanooga
State/Province
Tennessee
Country
United States
City
Hermitage
State/Province
Tennessee
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Austin
State/Province
Texas
Country
United States
City
Beaumont
State/Province
Texas
Country
United States
City
Byran
State/Province
Texas
Country
United States
City
Corsicana
State/Province
Texas
Country
United States
City
El Paso
State/Province
Texas
Country
United States
City
Fort Worth
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Bountiful
State/Province
Utah
Country
United States
City
Ogden
State/Province
Utah
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
City
West Jordan
State/Province
Utah
Country
United States
City
Chesapeake
State/Province
Virginia
Country
United States
City
Danville
State/Province
Virginia
Country
United States
City
Spokane
State/Province
Washington
Country
United States
City
Milwaukee
State/Province
Wisconsin
Country
United States
City
Monroe
State/Province
Wisconsin
Country
United States
City
Box Hill
Country
Australia
City
South Brisbane
Country
Australia
City
Sofia
Country
Bulgaria
City
Edmonton
State/Province
Alberta
Country
Canada
City
Winnipeg
State/Province
Manitoba
Country
Canada
City
St. John's
State/Province
Newfoundland and Labrador
Country
Canada
City
Quebec City
State/Province
Quebec
Country
Canada
City
Regina
State/Province
Saskatchewan
Country
Canada
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
City
Praha 6
Country
Czech Republic
City
Dietzenback
State/Province
HE
Country
Germany
City
Hamburg
State/Province
HH
Country
Germany
City
Schweim
State/Province
NW
Country
Germany
City
Borna
State/Province
SN
Country
Germany
City
Gyula
Country
Hungary
City
Gujarat
State/Province
Ahmedabad
Country
India
City
Tamilnadu
State/Province
Chennai
Country
India
City
Rajasthan
State/Province
Jaipur
Country
India
City
Ludhiana
State/Province
Punjab
Country
India
City
Madurai
State/Province
Tamina
Country
India
City
Chennai
Country
India
City
Coimbatore
Country
India
City
Hyderabad
Country
India
City
New Delhi
Country
India
City
Vishakapatnam
Country
India
City
Riga
Country
Latvia
City
Kaunas
Country
Lithuania
City
Hamilton
Country
New Zealand
City
Lima
Country
Peru
City
Krakow
Country
Poland
City
Lubin
Country
Poland
City
Sopot
Country
Poland
City
Warzawa
Country
Poland
City
Bratislava
Country
Slovakia
City
Nitra
Country
Slovakia
City
Sucany
Country
Slovakia
City
Tmava
Country
Slovakia
City
Gauteng
State/Province
Johannesburg
Country
South Africa
City
Cape Town
State/Province
WC
Country
South Africa
City
Panorama
State/Province
WC
Country
South Africa
City
Pinelands
State/Province
WC
Country
South Africa
City
Plumstead
State/Province
WC
Country
South Africa
City
Somerset West
State/Province
WC
Country
South Africa
City
Pretoria
Country
South Africa
12. IPD Sharing Statement
Citations:
PubMed Identifier
19183157
Citation
Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. Aliment Pharmacol Ther. 2009 Apr 1;29(7):731-41. doi: 10.1111/j.1365-2036.2009.03933.x.
Results Reference
result
PubMed Identifier
19735233
Citation
Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009 Nov 15;30(10):1010-21. doi: 10.1111/j.1365-2036.2009.04137.x. Epub 2009 Sep 4.
Results Reference
result
PubMed Identifier
20195905
Citation
Wyrwich KW, Mody R, Larsen LM, Lee M, Harnam N, Revicki DA. Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants. Qual Life Res. 2010 May;19(4):551-64. doi: 10.1007/s11136-010-9620-x. Epub 2010 Feb 27.
Results Reference
result
PubMed Identifier
21129076
Citation
Friedlander EA, Pallentino J, Miller SK, VanBeuge SS. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease. J Am Acad Nurse Pract. 2010 Dec;22(12):674-83. doi: 10.1111/j.1745-7599.2010.00578.x. Epub 2010 Nov 24.
Results Reference
result
PubMed Identifier
24118079
Citation
Peura DA, Pilmer B, Hunt B, Mody R, Perez MC. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013 Nov;38(10):1303-11. doi: 10.1111/apt.12504. Epub 2013 Sep 30.
Results Reference
derived
PubMed Identifier
23451835
Citation
Peura DA, Pilmer B, Hunt B, Mody R, Perez MC. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment Pharmacol Ther. 2013 Apr;37(8):810-8. doi: 10.1111/apt.12270. Epub 2013 Mar 4.
Results Reference
derived
Learn more about this trial
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
We'll reach out to this number within 24 hrs